Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases

 
• By Alaric DeArment
  
Biohaven and Higlightll signed a licensing deal worth up to $970m for Highlightll's brain-penetrant TYK2/JAK1 inhibitor • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business